JP2015511224A5 - - Google Patents
Download PDFInfo
- Publication number
- JP2015511224A5 JP2015511224A5 JP2014554840A JP2014554840A JP2015511224A5 JP 2015511224 A5 JP2015511224 A5 JP 2015511224A5 JP 2014554840 A JP2014554840 A JP 2014554840A JP 2014554840 A JP2014554840 A JP 2014554840A JP 2015511224 A5 JP2015511224 A5 JP 2015511224A5
- Authority
- JP
- Japan
- Prior art keywords
- alkyl
- isochromen
- amino
- pyrazin
- methylpiperazin
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Granted
Links
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| US201261591102P | 2012-01-26 | 2012-01-26 | |
| US61/591,102 | 2012-01-26 | ||
| PCT/US2013/023067 WO2013112788A1 (en) | 2012-01-26 | 2013-01-25 | Compounds for treating spinal muscular atrophy |
Related Child Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083760A Division JP2017171667A (ja) | 2012-01-26 | 2017-04-20 | 脊髄性筋萎縮症を治療するための化合物 |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2015511224A JP2015511224A (ja) | 2015-04-16 |
| JP2015511224A5 true JP2015511224A5 (enExample) | 2016-03-03 |
| JP6193888B2 JP6193888B2 (ja) | 2017-09-06 |
Family
ID=48873933
Family Applications (2)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2014554840A Active JP6193888B2 (ja) | 2012-01-26 | 2013-01-25 | 脊髄性筋萎縮症を治療するための化合物 |
| JP2017083760A Pending JP2017171667A (ja) | 2012-01-26 | 2017-04-20 | 脊髄性筋萎縮症を治療するための化合物 |
Family Applications After (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017083760A Pending JP2017171667A (ja) | 2012-01-26 | 2017-04-20 | 脊髄性筋萎縮症を治療するための化合物 |
Country Status (12)
| Country | Link |
|---|---|
| US (1) | US9399649B2 (enExample) |
| EP (1) | EP2809322B9 (enExample) |
| JP (2) | JP6193888B2 (enExample) |
| KR (1) | KR102064624B1 (enExample) |
| CN (1) | CN104203239B (enExample) |
| BR (1) | BR112014018027B1 (enExample) |
| CA (1) | CA2862084C (enExample) |
| EA (1) | EA028344B1 (enExample) |
| ES (1) | ES2733644T3 (enExample) |
| MX (1) | MX357834B (enExample) |
| PL (1) | PL2809322T3 (enExample) |
| WO (1) | WO2013112788A1 (enExample) |
Families Citing this family (37)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) * | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
| JP2016503051A (ja) * | 2012-12-24 | 2016-02-01 | ラモット・アット・テル−アヴィヴ・ユニヴァーシティ・リミテッド | ナンセンス変異に起因する遺伝性疾患を治療する作用剤、及びこれを同定する方法 |
| CA2915764A1 (en) | 2013-08-19 | 2015-02-26 | F. Hoffmann-La Roche Ag | Screening method |
| WO2015095446A1 (en) * | 2013-12-19 | 2015-06-25 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| WO2015105657A1 (en) | 2013-12-19 | 2015-07-16 | Ptc Therapeutics, Inc. | Methods for modulating the amount of rna transcripts |
| AU2015261046C1 (en) * | 2014-05-15 | 2019-07-25 | F. Hoffmann-La Roche Ag | Compounds for treating spinal muscular atrophy |
| US10882868B2 (en) | 2014-05-15 | 2021-01-05 | Hoffmann-La Roche Inc. | Compounds for treating spinal muscular atrophy |
| EP3310169B1 (en) | 2015-05-30 | 2023-05-17 | PTC Therapeutics, Inc. | Methods for modulating rna splicing |
| AU2016353961B2 (en) | 2015-11-12 | 2019-08-29 | F. Hoffmann-La Roche Ag | Compositions for treating spinal muscular atrophy |
| US10357543B2 (en) | 2015-11-16 | 2019-07-23 | Ohio State Innovation Foundation | Methods and compositions for treating disorders and diseases using Survival Motor Neuron (SMN) protein |
| CA3119019C (en) | 2015-12-10 | 2024-06-11 | Ptc Therapeutics, Inc. | Compounds and methods for treating huntington's disease |
| EP3386978B1 (en) | 2015-12-10 | 2021-01-27 | H. Hoffnabb-La Roche Ag | Bridged piperidine derivatives |
| JP6738044B2 (ja) * | 2016-07-22 | 2020-08-12 | Jnc株式会社 | ベンゾピラン骨格を有する液晶性化合物、液晶組成物、および液晶表示素子 |
| JP2019535789A (ja) | 2016-11-28 | 2019-12-12 | ピーティーシー セラピューティクス，インコーポレーテッド | Ｒｎａスプライシングを調節する方法 |
| EP4151627A1 (en) | 2017-06-05 | 2023-03-22 | PTC Therapeutics, Inc. | Compounds for treating huntington's disease |
| CN111372611A (zh) | 2017-06-14 | 2020-07-03 | Ptc医疗公司 | 修饰rna剪接的方法 |
| CN111163838B (zh) | 2017-06-28 | 2023-03-28 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| CN111182898B (zh) | 2017-06-28 | 2024-04-16 | Ptc医疗公司 | 用于治疗亨廷顿氏病的方法 |
| MX2020001425A (es) | 2017-08-04 | 2020-08-06 | Skyhawk Therapeutics Inc | Metodos y composiciones para modular el empalme. |
| BR112020019373A2 (pt) | 2018-03-27 | 2020-12-29 | Ptc Therapeutics, Inc. | Compostos para o tratamento da doença de hutington |
| KR20210038845A (ko) | 2018-06-27 | 2021-04-08 | 피티씨 테라퓨틱스, 인크. | 헌팅턴병 치료를 위한 헤테로아릴 화합물 |
| WO2020005882A1 (en) | 2018-06-27 | 2020-01-02 | Ptc Therapeutics, Inc. | Heteroaryl compounds for treating huntington's disease |
| WO2020004594A1 (ja) * | 2018-06-27 | 2020-01-02 | 株式会社リボルナバイオサイエンス | 脊髄性筋萎縮症の予防または治療剤 |
| IL279688B2 (en) | 2018-06-27 | 2025-01-01 | Ptc Therapeutics Inc | Heterocyclic and heteroaryl compounds for the treatment of Huntington's disease |
| WO2020163248A1 (en) | 2019-02-04 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| WO2020163541A1 (en) | 2019-02-05 | 2020-08-13 | Skyhawk Therapeutics, Inc. | Methods and compositions for modulating splicing |
| KR102913697B1 (ko) | 2019-02-05 | 2026-01-15 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| JP7603594B2 (ja) | 2019-02-06 | 2024-12-20 | スカイホーク・セラピューティクス・インコーポレーテッド | スプライシングを調節するための方法および組成物 |
| KR102925385B1 (ko) | 2019-02-06 | 2026-02-11 | 스카이호크 테라퓨틱스, 인코포레이티드 | 스플라이싱을 조절하는 방법 및 조성물 |
| CA3139821A1 (en) | 2019-05-13 | 2020-11-19 | Ptc Therapeutics, Inc. | Compounds for treating huntington's disease |
| US11129829B2 (en) | 2019-06-17 | 2021-09-28 | Skyhawk Therapeutics, Inc. | Methods for modulating splicing |
| AU2024286618A1 (en) * | 2023-06-09 | 2025-10-30 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
| WO2026125303A1 (en) * | 2024-12-11 | 2026-06-18 | F. Hoffmann-La Roche Ag | Inducible gene expression system |
Family Cites Families (23)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| JPS5854142B2 (ja) * | 1975-04-16 | 1983-12-02 | 株式会社興人 | イソカルボスチリル誘導体の製造方法 |
| US5089633A (en) * | 1987-04-28 | 1992-02-18 | Georgia Tech Research Corporation | Substituted isocoumarins |
| US6180625B1 (en) * | 1998-03-24 | 2001-01-30 | Novo Nordisk A/S | Heterocyclic compounds regulating clotting |
| WO2003005025A1 (en) * | 2001-07-03 | 2003-01-16 | Biovitrum Ab | Methods for identifying compounds modulating the activity of ppar-gamma |
| GB0205281D0 (en) | 2002-03-06 | 2002-04-17 | Novartis Ag | Organic compounds |
| WO2003104216A1 (en) * | 2002-06-10 | 2003-12-18 | Acadia Pharmaceuticals Inc. | Urotensin ii receptor modulators |
| PE20040728A1 (es) | 2002-06-28 | 2004-10-23 | Vertex Pharma | Inhibidores de caspasa |
| JP2004168707A (ja) * | 2002-11-20 | 2004-06-17 | Bayer Cropscience Ag | イソチアゾリルベンゾオキサジン誘導体および病害防除剤 |
| US9068234B2 (en) | 2003-01-21 | 2015-06-30 | Ptc Therapeutics, Inc. | Methods and agents for screening for compounds capable of modulating gene expression |
| ATE440825T1 (de) | 2003-06-06 | 2009-09-15 | Vertex Pharma | Pyrimidin-derivate zur verwendung als modulatoren von atp-bindende kassette transportern |
| US7399767B2 (en) | 2005-01-21 | 2008-07-15 | Ortho-Mcneil Pharmaceutical, Inc. | Heterocyclic benzo[c]chromene derivatives useful as modulators of the estrogen receptors |
| KR100781704B1 (ko) | 2005-04-20 | 2007-12-03 | 에스케이케미칼주식회사 | 피리딘 유도체와 이의 제조방법, 및 이를 포함하는약제조성물 |
| AR059339A1 (es) | 2006-02-09 | 2008-03-26 | Chugai Pharmaceutical Co Ltd | Derivados de la cumarina para trastornos proliferativos de celulas, composicion farmaceutica y agente terapeutico que los contiene |
| US8337941B2 (en) | 2006-07-27 | 2012-12-25 | The Trustees Of Columbia University In The City Of New York | Fluorescent substrates for monoamine transporters as optical false neurotransmitters |
| KR20080091949A (ko) * | 2007-04-10 | 2008-10-15 | 에스케이케미칼주식회사 | 락톤형 피리딘 화합물을 포함하는 허혈성 질환의 예방 및치료용 약학조성물 |
| JP5276878B2 (ja) * | 2007-09-27 | 2013-08-28 | 富士フイルム株式会社 | ベンゾオキサジノン系化合物の製造方法 |
| US8633019B2 (en) * | 2008-05-27 | 2014-01-21 | Ptc Therapeutics, Inc. | Methods for treating spinal muscular atrophy |
| WO2010019236A1 (en) | 2008-08-13 | 2010-02-18 | Ptc Therapeutics, Inc | Methods for treating spinal muscular atrophy |
| MX352861B (es) | 2011-12-30 | 2017-12-13 | Ptc Therapeutics Inc | Compuestos para tratar la atrofia muscular espinal. |
| MX357834B (es) * | 2012-01-26 | 2018-07-26 | Ptc Therapeutics Inc | Compuestos de tipo isocumarina sustituidos para tratar la atrofia muscular espinal. |
| EP3406252B1 (en) | 2012-02-10 | 2020-05-13 | PTC Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| US9371336B2 (en) | 2012-03-01 | 2016-06-21 | Ptc Therapeutics, Inc. | Compounds for treating spinal muscular atrophy |
| EP2828247B1 (en) | 2012-03-23 | 2019-01-16 | PTC Therapeutics, Inc. | 4h-chromen-4-one derivatives for treating spinal muscular atrophy |
-
2013
- 2013-01-25 MX MX2014008875A patent/MX357834B/es active IP Right Grant
- 2013-01-25 EA EA201491412A patent/EA028344B1/ru not_active IP Right Cessation
- 2013-01-25 KR KR1020147023617A patent/KR102064624B1/ko active Active
- 2013-01-25 CN CN201380016999.2A patent/CN104203239B/zh active Active
- 2013-01-25 PL PL13740919T patent/PL2809322T3/pl unknown
- 2013-01-25 US US14/373,937 patent/US9399649B2/en active Active
- 2013-01-25 JP JP2014554840A patent/JP6193888B2/ja active Active
- 2013-01-25 BR BR112014018027-0A patent/BR112014018027B1/pt active IP Right Grant
- 2013-01-25 WO PCT/US2013/023067 patent/WO2013112788A1/en not_active Ceased
- 2013-01-25 ES ES13740919T patent/ES2733644T3/es active Active
- 2013-01-25 EP EP13740919.9A patent/EP2809322B9/en active Active
- 2013-01-25 CA CA2862084A patent/CA2862084C/en active Active
-
2017
- 2017-04-20 JP JP2017083760A patent/JP2017171667A/ja active Pending
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| JP2015517988A5 (enExample) | ||
| JP2016504290A5 (enExample) | ||
| JP2015509956A5 (enExample) | ||
| NZ628186A (en) | Compounds for treating spinal muscular atrophy | |
| JP2015508075A5 (enExample) | ||
| JP2016529292A5 (enExample) | ||
| NZ600229A (en) | Triazolopyridines | |
| FI3406609T3 (fi) | Bisyklisiä atsayhdisteitä muskariinireseptorin agonisteina | |
| RU2012117796A (ru) | Производные пиразолиндиона как ингибиторы надфн-оксидазы | |
| RU2014152790A (ru) | Пирролопиразоновые ингибиторы танкиразы | |
| RU2015154676A (ru) | Соединения для лечения спинальной мышечной атрофии | |
| AR131260A2 (es) | Compuestos para tratar atrofia muscular espinal | |
| RU2011116230A (ru) | Пиразолопиридиновые производные как ингибиторы надфн-оксидазы | |
| ATE514699T1 (de) | Substituierte pyrrolopyrazolderivate als kinaseinhibitoren | |
| JP2016530283A5 (enExample) | ||
| JP2017510564A5 (enExample) | ||
| PE20090996A1 (es) | Derivados de pirrolopirimidina como inhibidores de cinasa jak3 | |
| PE20130611A1 (es) | Triazolopiridinas sustituidas | |
| JP2019500352A5 (enExample) | ||
| SE0402735D0 (sv) | Novel compounds | |
| RU2014107484A (ru) | ПРИМЕНЕНИЕ СОЕДИНЕНИЙ 2,3-ДИГИДРОИМИДАЗО[1,2-с]ПИРИМИДИН-5(1H)-ОНА В КАЧЕСТВЕ ИНГИБИТОРОВ LP-PLA2 | |
| WO2016142855A3 (en) | Pyrazolo[1,5-a][1,3,5]triazine and pyrazolo[1,5-a]pyrimidine derivatives as cdk inhibitors | |
| MX343014B (es) | Sales y formas cristalinas de un agente inductor de apoptosis. | |
| SMAP200900041A (it) | Sali e forme cristalline di 2-metil-2-[4-(3-metil-2-osso-8-chinolin-3-il-2,3-diidro-imidazo[4,5-c]chinolin-1il)-fenil]-propionitrile | |
| JP2016537384A5 (enExample) |